{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammatory+Myositis&page=2",
    "query": {
      "condition": "Inflammatory Myositis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammatory+Myositis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T02:55:29.936Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00059748",
      "title": "Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autoinflammatory Disease",
        "Juvenile Dermatomyositis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "2 Years to 100 Years"
      },
      "enrollment_count": 5000,
      "start_date": "2003-05-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00059748"
    },
    {
      "nct_id": "NCT06665256",
      "title": "Phase 2 Study of Rapcabtagene Autoleucel in Myositis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Inflammatory Myopathies"
      ],
      "interventions": [
        {
          "name": "Rapcabtagene autoleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Comparator Option",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 123,
      "start_date": "2024-12-17",
      "completion_date": "2032-11-29",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Zephyrhills, Florida • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Zephyrhills",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06665256"
    },
    {
      "nct_id": "NCT07115745",
      "title": "A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "BMS-986515",
          "type": "GENETIC"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2025-09-04",
      "completion_date": "2030-08-16",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07115745"
    },
    {
      "nct_id": "NCT04628936",
      "title": "Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Polymyositis",
        "Dermatomyositis"
      ],
      "interventions": [
        {
          "name": "KZR-616",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kezar Life Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2020-11-04",
      "completion_date": "2023-06-12",
      "has_results": true,
      "last_update_posted_date": "2025-11-19",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 9,
      "location_summary": "Beverly Hills, California • Orange, California • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04628936"
    },
    {
      "nct_id": "NCT05669014",
      "title": "A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Inflammatory Myositis"
      ],
      "interventions": [
        {
          "name": "Daxdilimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2023-12-04",
      "completion_date": "2025-07-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05669014"
    },
    {
      "nct_id": "NCT05738824",
      "title": "Natural History of Inflammatory Muscle Diseases",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inflammation In Skeletal Muscle"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "12 Years to 120 Years"
      },
      "enrollment_count": 500,
      "start_date": "2023-06-01",
      "completion_date": "2032-02-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05738824"
    },
    {
      "nct_id": "NCT07138898",
      "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatic Disease"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Golimumab",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab",
          "type": "DRUG"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Belimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anakinra",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ixekizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bimekizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ustekinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Guselkumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Risankizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2025-09",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-08-24",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07138898"
    },
    {
      "nct_id": "NCT01801917",
      "title": "Efficacy and Tolerability of BAF312 in Patients With Polymyositis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Polymyositis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BAF312",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 14,
      "start_date": "2013-04-24",
      "completion_date": "2016-08-05",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01801917"
    },
    {
      "nct_id": "NCT02347891",
      "title": "Belimumab in Idiopathic Inflammatory Myositis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Myositis"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2015-01",
      "completion_date": "2020-11",
      "has_results": true,
      "last_update_posted_date": "2024-02-09",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 1,
      "location_summary": "Great Neck, New York",
      "locations": [
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02347891"
    },
    {
      "nct_id": "NCT07103746",
      "title": "Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Disorders"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Ublituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-02-26",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-06-11T02:55:29.936Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07103746"
    }
  ]
}